Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Kevin Judice

Kevin Forrest

Cidara Therapeutics, Inc.

Cidara Therapeutics is a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing cancer and other serious diseases.

National Institutes of Health

CARB-X

Square 1 Bank

venBio Partners

Rock Springs Capital

Sabby Capital

5AM Ventures

Aisling Capital

RA Capital Management

Fidelity

Cidara Therapeutics

Today our treatment for adults with invasive candidiasis has been approved by the United Kingdom MHRA. Read here for more information on this milestone: https://brnw.ch/21wGuRc

In case you missed it, the European Commission approved our treatment for adults with invasive candidiasis, triggering an $11M milestone payment that we will use to continue the development of our Cloudbreak platform in oncology. Learn more about the approval: https://brnw.ch/21wFMcE

Today, we announced our treatment option for adults with invasive candidiasis has been approved in the European Union. Read more about this significant milestone for patients here: https://brnw.ch/21wFxOY

We’re excited to share we presented new preclinical data at the ESMO - European Society for Medical Oncology Immuno-Oncology Congress, demonstrating anti-tumor activity of our multi-specific CD73/PD-1 inhibitor drug-Fc conjugate (DFC) candidate. Read more: https://brnw.ch/21wF786 #ESMOImmuno23

Metric
Company Name	Cidara Therapeutics, Inc.
Symbol	CDTX
MSH ID	COM:CIDARA
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	69
Website	cidara.com
LinkedIn	cidara-therapeutics
Founders

Metric
Market Cap	51.64M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	63.91M
Revenue (LTM)
Revenue (NTM)
Gross Profit	62.38M
EBITDA	-24.37M
Operating Income	-24.48M
Net Income	-22.93M
EPS	-0.26
Diluted EPS	-0.26
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.98
Operating Profit Margin	-0.38
EBITDA Margin	-0.38
Net Profit Margin	-0.37
Return on Equity	57.47
Return on Assets	-0.34
Return on Capital Employed	3.00

COM:CIDARA

Cidara Therapeutics, Inc.

Last Close

17.45

22/11 21:00

Market Cap

51.64M

Beta: -

Volume Today

219.11K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.95
P/B Ratio	7.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	2.34
EV Multiple	-1.94

Metric
Days Sales Outstanding	18.43
Days Payables Outstanding	3.45K
Days Inventory Outstanding	991.71
Operating Cycle	1.08K
Cash Conversion Cycle	470.97
Asset Turnover	0.93

Metric
Operating Cash Flow	-22.43M
Free Cash Flow	-22.94M
Cash Flow to Debt	-3.91
Operating Cash Flow/Sales	-0.35
Free Cash Flow Yield	-0.42

Metric
Cash & Equivalents	35.78M
Accounts Receivable	-10.41M
Inventory	6.10M
Goodwill
Debt to Capitalization	0.35
Debt to Assets	0.07
Current Ratio	1.62
Quick Ratio	4.25

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.05
R&D to Revenue	1.30
SG&A to Revenue	0.26